Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions
Parkinson's Disease
Interventions
DRUG

BIIB014

oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks

DRUG

Placebo

Matched placebo for MTD or MTD-1

Trial Locations (15)

Unknown

Research Sites, Bangalore

Research Site, Chennai

Research Site, Hyderabaad

Research Site, Ludhiana

Research Site, Mumbai

Research Site, New Delhi

Research Site, Secunderabad

Research Site, Ashkelon

Research Site, Jerusalem

Research Site, Ramat Gan

Research Site, Tel Aviv

Research Site, Cambridge

Research Site, Manchester

Research Site, Norwich

Research Site, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY